How are GMO Regulations Impacting Clinical Development in Europe?

Update: 2024-04-25

Description

In this episode of Conversations in Drug Development, our host Harriet Edwards, is joined by Director of Regulatory Affairs, Dr Sabine Ruehle, to discuss the challenges of navigating genetically modified organism (GMO) regulations in clinical trials within Europe. This discussion helps decipher the nuanced environment of GMOs and their associated risks unique within the European framework. Join us as we explore the outdated definition of GMOs, the complexities of their classification, and the impact of genome editing technologies.

Comments

Top Podcasts

The Best New Comedy Podcast Right Now – June 2024 The Best News Podcast Right Now – June 2024 The Best New Business Podcast Right Now – June 2024 The Best New Sports Podcast Right Now – June 2024 The Best New True Crime Podcast Right Now – June 2024 The Best New Joe Rogan Experience Podcast Right Now – June 20 The Best New Dan Bongino Show Podcast Right Now – June 20 The Best New Mark Levin Podcast – June 2024

In Channel

Patients as Partners: Advocacy's Role in Shaping Drug Development

2024-11-0827:24

Navigating the Future of EU Health Technology Assessments

2024-10-1629:10

A Guide to Marketing Authorisation Applications in Europe

2024-09-2428:19

Navigating the new EU Clinical Trials Regulation

2024-08-1328:26

Advances in Cell-Based Immunotherapies: CAR-T Cell Therapy vs TCR Therapy

2024-07-2528:10

Demystifying Regulatory Designations in Drug Development

2024-07-1025:53

Exploring Genome Editing Technologies in Drug Development

2024-06-1923:44